Summary

Several multi-cancer early detection (MCED) tests based on novel blood-based biomarkers, such as cell-free DNA (cfDNA) or circulatory miRNA, help to make cancer screening cost-effective and more accessible by complementing current standard-of-care clinical diagnostic tests. This review by A/Prof Too Heng-Phon and team summarizes clinical utility of circulatory miRNAs for early disease detection and highlights point-of-care testing (POCT) for earlier detection of cancer for intervention with precision medicine.

Link to article: https://bit.ly/3vJI5V0